{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:07:55Z","timestamp":1779361675589,"version":"3.51.4"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82101143"],"award-info":[{"award-number":["82101143"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQ20C120001"],"award-info":[{"award-number":["LQ20C120001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glioma, the most prevalent malignant intracranial tumor, poses a significant threat to patients due to its high morbidity and mortality rates, but its prognostic indicators remain inaccurate. Although TRAF-associated NF-kB activator (TANK) interacts and cross-regulates with cytokines and microenvironmental immune cells, it is unclear whether TANK plays a role in the immunologically heterogeneous gliomas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>TANK mRNA expression patterns in public databases were analyzed, and qPCR and IHC were performed in an in-house cohort to confirm the clinical significance of TANK. Then, we systematically evaluated the relationship between TANK expression and immune characteristics in the glioma microenvironment. Additionally, we evaluated the ability of TANK to predict treatment response in glioma. TANK-associated risk scores were developed by LASSO-Cox regression and machine learning, and their prognostic ability was tested.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TANK was specifically overexpressed in glioma and enriched in the malignant phenotype, and its overexpression was related to poor prognosis. The presence of a tumor microenvironment that is immunosuppressive was evident by the negative correlations between TANK expression and immunomodulators, steps in the cancer immunity cycle, and immune checkpoints. Notably, treatment for cancer may be more effective when immunotherapy is combined with anti-TANK therapy. Prognosis could be accurately predicted by the TANK-related risk score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High expression of TANK is associated with the malignant phenotype of glioma, as it shapes an immunosuppressive tumor microenvironment. Additionally, TANK can be used as a predictive biomarker for responses to various treatments and prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.1138203","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:56:24Z","timestamp":1683248184000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["TANK shapes an immunosuppressive microenvironment and predicts prognosis and therapeutic response in glioma"],"prefix":"10.3389","volume":"14","author":[{"given":"Shasha","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youwei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.586019","article-title":"Three immune-associated subtypes of diffuse glioma differ in immune infiltration, immune checkpoint molecules, and prognosis","volume":"10","author":"Zhou","year":"2020","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.3390\/ijms18122609","article-title":"Molecular and genetic determinants of glioma cell invasion","volume":"18","author":"Masui","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou153","article-title":"New concepts in the management of diffuse low-grade glioma: proposal of a multistage and individualized therapeutic approach","volume":"17","author":"Duffau","year":"2015","journal-title":"Neuro Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.204","article-title":"Advances in the molecular genetics of gliomas - implications for classification and therapy","volume":"14","author":"Reifenberger","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.12.028","article-title":"Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma","volume":"164","author":"Ceccarelli","year":"2016","journal-title":"Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 world health organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","article-title":"Overcoming the blood-brain tumor barrier for effective glioblastoma treatment","volume":"19","author":"van Tellingen","year":"2015","journal-title":"Drug Resist Update"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.679425","article-title":"Immune checkpoint inhibitors in human glioma microenvironment","volume":"12","author":"Ghouzlani","year":"2021","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0516-0","article-title":"Oncolytic virotherapy for the treatment of malignant glioma","volume":"14","author":"Foreman","year":"2017","journal-title":"Neurotherapeutics"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.266","article-title":"The market for chimeric antigen receptor T cell therapies","volume":"17","author":"Yip","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000469682","article-title":"Cytokine therapy of gliomas","volume":"32","author":"Iwami","year":"2018","journal-title":"Prog Neurol Surg"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-015-3958-1","article-title":"In situ dendritic cell vaccination for the treatment of glioma and literature review","volume":"37","author":"Li","year":"2016","journal-title":"Tumour Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1823","article-title":"CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma","volume":"18","author":"Prieto","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis c","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.08.1048","article-title":"Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities","volume":"154","author":"Suresh","year":"2018","journal-title":"Chest"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.9b03968","article-title":"Aggregable nanoparticles-enabled chemotherapy and autophagy inhibition combined with anti-PD-L1 antibody for improved glioma treatment","volume":"19","author":"Ruan","year":"2019","journal-title":"Nano Lett"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03459-y","article-title":"Repolarized macrophages, induced by intermediate stereotactic dose radiotherapy and immune checkpoint blockade, contribute to long-term survival in glioma-bearing mice","volume":"147","author":"Stessin","year":"2020","journal-title":"J Neurooncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2070","article-title":"Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function","volume":"13","author":"Fecci","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1535","article-title":"Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas","volume":"23","author":"Kim","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.16.8241","article-title":"I-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction","volume":"93","author":"Rothe","year":"1996","journal-title":"Proc Natl Acad Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1101\/gad.10.8.963","article-title":"TANK, a co-inducer with TRAF2 of TNF- and CD 40L-mediated NF-kappaB activation","volume":"10","author":"Cheng","year":"1996","journal-title":"Genes Dev"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.93.20.11085","article-title":"Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa b activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein","volume-title":"Proc Natl Acad Sci USA","author":"Kaye","year":"1996"},{"key":"B28","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1600-065X.2012.01099.x","article-title":"NF-\u03baB and the link between inflammation and cancer","volume":"246","author":"Didonato","year":"2012","journal-title":"Immunol Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2443.2000.00315.x","article-title":"NF-\u03baB activation through IKK-i-dependent I-TRAF\/TANK phosphorylation - nomura - 2001 - genes to cells - Wiley online library","volume":"5","author":"Nomura","year":"2000","journal-title":"Genes to Cells"},{"key":"B30","doi-asserted-by":"publisher","first-page":"a001651","DOI":"10.1101\/cshperspect.a001651","article-title":"The nuclear factor NF-kappaB pathway in inflammation","volume":"1","author":"Lawrence","year":"2009","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M205069200","article-title":"Association of the adaptor TANK with the I kappa b kinase (IKK) regulator NEMO connects IKK complexes with IKK epsilon and TBK1 kinases","volume":"277","author":"Chariot","year":"2002","journal-title":"J Biol Chem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M700017200","article-title":"Modulation of the interferon antiviral response by the TBK1\/IKKi adaptor protein TANK","volume":"282","author":"Guo","year":"2007","journal-title":"J Biol Chem"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1114194108","article-title":"The TRAF-associated protein TANK facilitates cross-talk within the IkappaB kinase family during toll-like receptor signaling","volume":"108","author":"Clark","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B34","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1089\/dna.2004.23.826","article-title":"Genomic and proteomic expression patterns in HPV-16 E6 gene transfected stable human carcinoma cell lines","volume":"23","author":"Yim","year":"2004","journal-title":"DNA Cell Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2006.00586.x","article-title":"Analysis of differential protein expression by cisplatin treatment in cervical carcinoma cells","volume":"16","author":"Yim","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2013.42","article-title":"Deregulated expression of TANK in glioblastomas triggers pro-tumorigenic ERK1\/2 and AKT signaling pathways","volume":"2","author":"Stellzig","year":"2013","journal-title":"Oncogenesis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.899883","article-title":"SYK is associated with malignant phenotype and immune checkpoints in diffuse glioma","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Genet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.7150\/thno.53649","article-title":"Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer","volume":"11","author":"Hu","year":"2021","journal-title":"Theranostics"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0689","article-title":"TIP: a web server for resolving tumor immunophenotype profiling","volume":"78","author":"Xu","year":"2018","journal-title":"Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0157-9","article-title":"Robust\u00a0prediction of response to immune checkpoint blockade therapy in metastatic\u00a0melanoma","volume":"24","author":"Auslander","year":"2018","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"12833","DOI":"10.1038\/s41598-019-49226-6","article-title":"Prediction of soil available water-holding capacity from visible near-infrared reflectance spectra","volume":"9","author":"Blaschek","year":"2019","journal-title":"Sci Rep"},{"key":"B44","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1038\/s41467-021-24347-7","article-title":"Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma","volume":"12","author":"van Hooren","year":"2021","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2000906","DOI":"10.1002\/advs.202000906","article-title":"Charge and size dual switchable nanocage for novel triple-interlocked combination therapy pattern","volume":"7","author":"Yang","year":"2020","journal-title":"Adv Sci (Weinh)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/imr.12762","article-title":"T-Cell positioning by chemokines in autoimmune skin diseases","volume":"289","author":"Richmond","year":"2019","journal-title":"Immunol Rev"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/s41467-019-09963-8","article-title":"Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo","volume":"10","author":"Tulic","year":"2019","journal-title":"Nat Commun"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2598","article-title":"Tumor purity as an underlying key factor in glioma","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.02.020","article-title":"NEMO prevents RIP kinase 1-mediated epithelial cell death and chronic intestinal inflammation by NF-kappaB-Dependent and -independent functions","volume":"44","author":"Vlantis","year":"2016","journal-title":"Immunity"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1874735","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1138203\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T10:35:44Z","timestamp":1779359744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1138203\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2023.1138203"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1138203","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"article-number":"1138203"}}